A Review of the Sutezolid (PNU-100480) Patent Landscape: A Scoping Report

Sutezolid belongs to the oxazolidinone class of compounds, which function as protein synthesis inhibitors and were first discovered in the mid-1980s. Linezolid was the first compound of the oxazolidinone class to be approved for treatment of TB. It is most commonly used to treat drug-resistant TB. However, linezolid’s use has been limited by toxicity concerns, particularly haematological effects after periods of treatment over 14 days.

Given the potential of sutezolid, this report explores the patent landscape and considers possible access issues relating to the drug should it become available on the market.